MG News Briefs

antibodies

Antibody Status Impacts Disease Severity in MG

Patients with myasthenia gravis (MG) who are positive for a combination of both anti-acetylcholine receptor (AChR) and anti-Titin antibodies (AChR+Titin-MG) had more severe symptoms and progressed faster than patients with only anti-AChR (AChR-MG), and those with anti-AChR in combination with anti-low-density lipoprotein receptor-related protein 4 (LRP4) antibodies (AChR+LRP-MG), as published in Frontiers in Neurology. Patients…

group

People With Rare Diseases Report Facing Stigma, Poor Quality of Life

People with rare diseases who live in the United States have a poor health-related quality of life and experience significant stigma, according to a study published in the Orphanet Journal of Rare Diseases. A rare disease in the United States can be defined as any disease in which the prevalence is less than 200,000 cases.…

clinical trial research

Phase 3 Myasthenia Gravis Trials Yield Positive Results for 2 Potential Therapies

Positive results from 2 phase 3 clinical trials of potential generalized myasthenia gravis (gMG) therapies were recently presented as posters at the 14th Myasthenia Gravis Foundation of America (MGFA) International Conference on Myasthenia and Related Disorders. The 2 therapies, zilucoplan and rozanolixizumab, were both associated with improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL)…

online questionnaire

Quality of Life Questionnaire Recommended When Treating Myasthenia Gravis

Researchers studying the accuracy of quality of life (QoL) scales in patients with myasthenia gravis recommended their use in clinical practice because some symptoms of the disease can be difficult to examine, according to a study published in the Journal of Clinical Medicine.  Myasthenia gravis is an autoimmune disease in which the neuromuscular junction is…

dna sequencing

Case Studies Suggest Etiopathogenetic Link Between NMOSD and Myasthenia Gravis

Two cases of coexisting neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis (MG) suggest a possible etiopathogenetic link between the diseases, reports a study published in Multiple Sclerosis and Related Disorders. Using next-generation sequencing (NGS), 2 mutant human leukocyte antigen (HLA) alleles were found in common between the 2 patients—HLA-DQA1*05:01:01 and HLA-DPB1*04:02:01. “To summarize, although…

covid vaccines

Benefits of COVID-19 Vaccine Outweigh the Risks in MG, Study Suggests

Researchers assessing the safety of vaccines for patients with myasthenia gravis (MG) found that some of them, such as the anti-SARS-CoV-2, may cause MG exacerbations, but evidence points overwhelmingly in favor that they are still recommended for these patients, as published in the Journal of Neurology. MG, a chronic autoimmune disease affecting the neuromuscular junction,…

plasma

Lymphoplasma Exchange Effective in Some Myasthenia Gravis Cases

Lymphoplasma exchange is an effective treatment for patients with myasthenia gravis who are in a state of exacerbation or in preparation for a thymectomy, according to a new retrospective study performed in a Chinese center. According to the authors of the study, published in Frontiers in Immunology, the early use of lymphoplasma exchange on early-onset…

respiratory care

Preoperative Anti-MG Drugs Associated With Severe Respiratory Failure

Researchers found that myasthenia gravis (MG) grade 3 and the preoperative administration of anti-MG drugs are associated with a higher incidence of severe respiratory failure and a greater need for postoperative ventilator support after thymoma surgery, as published in the Journal of Surgical Research. They also noted additional risk factors such as sex, Masaoka thymoma…

FDA approved

FDA Approves Ravulizumab-cwvz for Adults With Myasthenia Gravis

The US Food and Drug Administration (FDA) approved ravulizumab-cwvz (Ultomiris®) by Alexion for the treatment of adults with generalized myasthenia gravis (MG) who are positive for the anti-acetylcholine receptor (AChR) antibody. This represents 80% of all patients with MG. “With the approval of ULTOMIRIS, we’re excited that MG patients now have another option to consider…

Next post in MG News Briefs